Idera Pharmaceuticals, Inc. (IDRA) to Present at the 3rd Annual Cancer Immunotherapy Conference  
9/28/2012 10:35:10 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, (NASDAQ: IDRA) a biotechnology company developing Toll-like receptor candidates for the treatment of autoimmune diseases and for use as vaccine adjuvants, today announced that members of the management team will be presenting at the third annual “Cancer Immunotherapy: A Long-Awaited Reality Conference” at the New York Academy of Medicine in New York City. The presentation will be made on Thursday, October 4, 2012 in Room 21 from 11:00 to 11:15 am.